Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Common Equity (2018 - 2025)

Historic Common Equity for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $224.6 million.

  • Arcturus Therapeutics Holdings' Common Equity fell 1424.66% to $224.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.6 million, marking a year-over-year decrease of 1424.66%. This contributed to the annual value of $241.0 million for FY2024, which is 1347.69% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Common Equity of $224.6 million as of Q3 2025, which was down 1424.66% from $231.1 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Common Equity registered a high of $352.6 million during Q1 2021, and its lowest value of $145.7 million during Q3 2022.
  • Moreover, its 5-year median value for Common Equity was $259.1 million (2021), whereas its average is $252.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 197635.73% in 2021, then plummeted by 4760.48% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Common Equity (Quarter) stood at $228.2 million in 2021, then increased by 18.45% to $270.3 million in 2022, then rose by 3.03% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 6.81% to $224.6 million in 2025.
  • Its Common Equity was $224.6 million in Q3 2025, compared to $231.1 million in Q2 2025 and $233.8 million in Q1 2025.